Research Article of International Journal of Dental Research and Reviews
Assessment the effect of the use of bisphosphonates on dental implant rehabilitation and peri-implant tissues
Rebecca Ellen Mayall, DDS1, Cimara Fortes Ferreira, DDS, MSc, PhD1, Russell Anthony Wicks, DDS, MSc3, Felipe Fabrício Farias da Silva, DDS4
1Assistant Professor, Department of Prosthodontics, University of Tennessee Health Sciences College of Dentistry, Memphis, TN. 2 Assistant Professor, Department of Prosthodontics, University of Tennessee Health Sciences College of Dentistry, Memphis, TN. 3Professor, Chair, Department of Prosthodontics. University of Tennessee Health Sciences College of Dentistry, Memphis, TN. 4Private practice, Quixeramobim, Ceará, Brazil.
Background: Long-term use of bisphosphonates (BP) has been associated with the risk of BP-related osteonecrosis of the jaw (BRONJ). The number of post-menopausal women receiving BP therapy for osteoporosis continues to increase as the life expectancy increases. Dental implant rehabilitations have progressed over the years. The purpose of the present study was to evaluate the peri-implant conditions of patients taking oral or intravenous (IV) BPs.
Methods: This was a retrospective study using an ORACLE database search by means of a Procedural Language/Structured Query engine. Fifty female patients with dental implant rehabilitations and taking bisphosphonates, and fifty female patients with dental implants but not taking BP were evaluated. Peri-implant health and rehabilitation conditions were collected and statistics analyzed.
Results: Data analysis revealed a strong indication (p<0.01; 82.81%) of the use of bisphosphonates and absence of abscesses. Relative risk indicated 25 times more chance of a person that does not use bisphosphonates to develop abscess when compared with people using bisphosphonates. This shows that the use of bisphosphonates may play a protecting role in the patients with dental implants. Alternatively, there was a strong indication (p<0.01) of existence of association between the occurrence of mucositis and the use of bisphosphonates. Most of the cases of mucositis (94.44%) occurred in patients that used bisphosphonates while the majority of the cases where mucositis did not occur (59.76%) referred to the group being treated with bisphosphonates.
Conclusion: This study revealed that there was absence of indications of significant associations between doses of bisphosphonates and the occurrence of peri-implant diseases.
Keywords: Implantology, osseointegration, osseoporosis, periodontitis, prosthodontics.
How to cite this article:
Rebecca Ellen Mayall, Cimara Fortes Ferreira,Russell Anthony Wicks, Felipe Fabrício Farias da Silva. Assessment the effect of the use of bisphosphonates on dental implant rehabilitation and peri-implant tissues. International Journal of Dental Research and Reviews, 2020, 3:36. DOI: 10.28933/ijdrr-2020-04-1605
1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
2. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4254.
3. Hampson G, Fogelman I. Clinical role of bisphosphonate therapy. Int J Womens Health 2012;4:455-469.
4. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2011;1218:47-54.
5. Famili N. Oral Bisphosphonates and Relationship to ONJ and Dental Implants. Dentistry 2013:1.
6. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66:223-230.
7. Tong N. Osseointegrated implants, osteoporosis and bisphosphonate therapy: a literature review. . Dentistry 2016:34-40.
8. Chrcanovic BR, Albrektsson T, Wennerberg A. Bisphosphonates and dental implants: A meta-analysis. Quintessence Int 2016;47:329-342.
9. Zahid TM, Wang BY, Cohen RE. Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J Oral Implantol 2011;37:335-346.
10. Wagenberg B, Froum SJ. A retrospective study of 1925 consecutively placed immediate implants from 1988 to 2004. Int J Oral Maxillofac Implants 2006;21:71-80.
11. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 2008;66:1022-1024.
12. Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 2009;37:39-42.
13. Verde ME, Bermejo D, Gruppi A, Grenon M. Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis. Acta Odontol Latinoam 2015;28:215-221.
14. Bhavsar NV, Trivedi SR, Dulani K, Brahmbhatt N, Shah S, Chaudhri D. Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study). Osteoporos Int 2016;27:2611-2619.
15. Grgic O, Kovacev-Zavisic B, Veljovic T, Novakovic-Paro J, Maravic T, Bajkin B. The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women. Clin Oral Investig 2017;21:151-157.
16. Reiss S, Sultan D. Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis. N Y State Dent J 2015;81:30-33.
17. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grotz KA. Dental implants in patients treated with antiresorptive medication – a systematic literature review. Int J Implant Dent 2016;2:9.
18. Marin-Fernandez AB, Garcia Medina B, Aguilar-Salvatierra A, Jimenez-Burkhardt A, Gomez-Moreno G. Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid. J Clin Exp Dent 2015;7:e444-446.
19. Martin DC, O’Ryan FS, Indresano AT, et al. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg 2010;68:508-514.
20. Mattheos N, Caldwell P, Petcu EB, Ivanovski S, Reher P. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. J Can Dent Assoc 2013;79:d2.
21. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
22. Yip JK, Borrell LN, Cho SC, Francisco H, Tarnow DP. Association between oral bisphosphonate use and dental implant failure among middle-aged women. J Clin Periodontol 2012;39:408-414.
23. Pereira FM, Rodrigues VP, de Oliveira AE, Brito LM, Lopes FF. Association between periodontal changes and osteoporosis in postmenopausal women. Climacteric 2015;18:311-315.